RecruitingOropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+ locoregionally advanced oropharyngeal cancer (OPC).
Sponsor: University of Chicago
You may qualify if…
- ✓ Subjects must have pathologically confirmed HPV16-positive head and neck squamous cell carcinoma of the oropharynx. Confirmed HPV-positive disease of other subsites are uncommon but also eligible.
- ✓ HPV16 subtype demonstrated based on the following guidelines:
- ✓ p16 IHC positivity is sufficient to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by Jordan and Lingen et al72).
- ✓ HPV PCR must demonstrate HPV16 subtype.
- ✓ Following p16 IHC positivity, HPV16 is to be demonstrated using HPV PCR which is anticipated to result prior to cycle 1 day 15.
- ✓ Patients must be at least 18 years of age.
- ✓ Subjects with AJCC (8th edition, 2018) N1 (if solitary lymph node must be \>=3cm), N2-N3 nodal disease or T3-T4 primary tumor (with any N).
- ✓ Measurable disease (either primary site and/or nodal disease) by RECIST 1.1 criteria.
You may not qualify if…
- ✕ Unequivocal demonstration of distant metastatic disease (M1 disease).
- ✕ Non-HPV16 subtype.
- ✕ Unidentifiable primary site.
- ✕ Intercurrent medical illnesses that impairs the patient's tolerance to therapy or limits survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility).
- ✕ Subject with low risk N1 disease (defined as single lymph node \<3cm)
- ✕ Active, known, or suspected, autoimmune or inflammatory disorders requiring immunosuppressive therapy, with the exception of low-dose prednisone (\<= 10mg or equivalent). The following are exceptions to these criteria:
- ✕ Patients with vitiligo or alopecia.
- ✕ Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
Where it's recruiting
Illinois
Chicago
Source: ClinicalTrials.gov · NCT07290621 · last updated 2026-02-06